Friday, September 30, 2022

561.316.3330

Biotechnology News Magazine

PhenoVue 1st Cell Painting Kit Launched by Perkin Elmer

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

February 18, 2021

PhenoVue cellular imaging reagents is a new portfolio for Perkin Elmer.

This new range of reagents leverages their expertise in cellular imaging and high-content screening and works alongside the Company’s microplates, automation, software and industry-leading high-content screening instruments.

With this entire screening workflow, researchers can better understand disease and develop more pinpointed therapies and drugs to treat them.

Cell painting is a powerful application of high-content screening technology which combines cell and computational biology to study the effects of perturbagens such as chemical compounds, drugs or genes on the behavior of cells. Cells are “painted” by labelling cellular compartments with different fluorescent bioprobes to enable those areas to be quantitatively profiled. However, preparing reagents from scratch can be incredibly time consuming.

Helping to address this challenge, the PhenoVue™ cell painting kit provides convenience and simplicity through a ready-to-use format and is part of a new range of reagents that also includes fluorescent organelle staining probes and dye-labelled secondary antibodies. These reagents are validated for high-content screening applications to reduce customers’ assay development time. For example, customers can use these reagents with PerkinElmer’s CellCarrier™ Ultra microplates, the PerkinElmer Opera Phenix® Plus high-content screening system, Operetta CLS™ high-content analysis system and Harmony® high-content analysis software.

“Researchers are using high-content screening and cell painting to make extraordinary discoveries that will help drive more innovative drugs and therapies,” said Alan Fletcher, Vice President and GM of Life Sciences, PerkinElmer. “With the addition of our new PhenoVue™ cellular imaging reagents, we now offer a complete suite of high-content screening products and expert services. This will help researchers build more streamlined workflows and enjoy the convenience of working with a single, expert technology provider helping to accelerate discovery.”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine